Home / Resources / Videos / ADA 2017 / Thomas Seck Part 7, The Future For Boehringer Ingelheim

Thomas Seck Part 7, The Future For Boehringer Ingelheim

In part 7 of this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about what’s coming up next for Boehringer Ingelheim and Eli Lilly, and knowing the right patient to treat with the newest drugs.

Thomas Seck, MD, is VP of Clinical Development and Medical Affairs at Boehringer Ingelheim.

Transcript of this video segment:

Steve: And how is your relationship with Lilly expanding your portfolio? What’s in the pipeline? What’s coming up next?

Dr. Seck: So overall, the alliance was established in 2011, so we are now together for number of years and so far it’s been a very collaborative partnership. I think we are really combining the expertise of two top pharmaceutical companies to really provide value for patients with type 2 diabetes. And I think if you look at the product that we made available over the last 6 years, we have launched 8 products. So I think that’s a clear testament providing all these treatment options for the management of type 2 diabetes how successful and how well this alliance between Boehringer Ingelheim and Eli Lilly is operating.

Steve: So what do you think about putting the pharmaceutical drug we have been talking about in the water?

Dr. Seck: In general, I hope its not a serious statement, but in general I think its important to identify the appropriate patient. Right? And that’s why education is so important. Right? Education to physicians that prescribes the drug to make sure they understand the profile, the benefits and the risks associated with it and that is important for physician. On the other side, I think what’s also important in the space is that we need to start educating patients about it as well. The link between cardiovascular disease and diabetes is very well established for physicians. What we have found in some market research that we have conducted is that the awareness of the connection between diabetes and cardiovascular disease is very poor in patients. And therefore also as an alliance, we took it on to have an unbranded campaign, Called for Your Sweet Heart, to really highlight that connection because I think if patient understand “I am at risk for cardiovascular disease” they will be motivated to actively be engaged in the management of diabetes and to reduce the risk of important and clinically meaningful cardiovascular events.

Steve: Don’t most people with type 2 diabetes, couldn’t you say that they are all at risk for cardiovascular disease if they don’t take care of their cholesterol, their hypertension and all the other things that go with it?                                       

Dr. Seck: Yes, you are absolutely correct. The presence of type 2 diabetes is a cardiovascular risk equivalent. So if you have diabetes even without cardiovascular disease, your risk for having a cardiovascular event is clearly increased. You are absolutely correct.

Return to the main page.